

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **VOLUNTARY ANNOUNCEMENT**

## **BIOCYTOGEN ENTERED INTO MULTI-TARGET ANTIBODY AGREEMENT WITH NEUROCRINE BIOSCIENCES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**” or “**Biocytogen**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Company has entered into an antibody evaluation and option agreement (the “**Agreement**”) with Neurocrine Biosciences, Inc. (“**Neurocrine Biosciences**”). The Agreement granted Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide. In future, additional targets may be included under this Agreement subject to mutual agreement. The antibodies were generated by Biocytogen’s proprietary RenMice® platforms.

Under the terms of the Agreement, if the options are exercised by Neurocrine Biosciences, Biocytogen will be entitled to option-exercise fees, development and commercialization milestone payments, as well as single-digit royalties on net sales for each selected target.

Dr. Yuelel Shen, the chairman of the Board, chief executive officer and executive Director of the Company said, “We are pleased that our RenMice®-derived fully human antibodies received recognition from Neurocrine Biosciences, a world-leading neuroscience-focused biopharmaceutical company. We are optimistic that the combination of our comprehensive, validated off-the-shelf antibody sequences and Neurocrine Biosciences’ extensive experience in novel drug development will accelerate the path to help conquer neurological diseases that are difficult to treat.”

“We are excited to evaluate the therapeutic potential of antibodies generated from Biocytogen’s renowned fully human antibody platforms,” said Jude Onyia, Ph.D., chief scientific officer at Neurocrine Biosciences. “We believe this collaboration will help expand our pipeline with antibody-based drugs and ultimately provide patients with improved treatment options.”

To the best knowledge and belief of the Directors, as of the date of this announcement, Neurocrine Biosciences and its ultimate beneficial owners are independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

**This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**

**Shen Yuele**

*Chairman of the Board, Chief Executive Officer and Executive Director*

Hong Kong, December 20, 2023

*As at the date of this announcement, the Board comprises Dr. Shen Yuele as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*

## **Biocytogen Entered into Multi-Target Antibody Agreement with Neurocrine Biosciences**

Beijing, China and San Diego, US, December 20, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“**Biocytogen**” or “**Company**”) (Stock Code: 02315.HK) announced that the Company has entered into an antibody evaluation and option agreement (the “**Agreement**”) with Neurocrine Biosciences, Inc. (“**Neurocrine Biosciences**”). The Agreement granted Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide. In future, additional targets may be included under this Agreement subject to mutual agreement. The antibodies were generated by Biocytogen’s proprietary RenMice® platforms.

Under the terms of the Agreement, if the options are exercised by Neurocrine Biosciences, Biocytogen will be entitled to option-exercise fees, development and commercialization milestone payments, as well as single-digit royalties on net sales for each selected target.

Dr. Yuelei Shen, the chairman of the Board, chief executive officer and executive Director of the Company said, “We are pleased that our RenMice®-derived fully human antibodies received recognition from Neurocrine Biosciences, a world-leading neuroscience-focused biopharmaceutical company. We are optimistic that the combination of our comprehensive, validated off-the-shelf antibody sequences and Neurocrine’s extensive experience in novel drug development will accelerate the path to help conquer neurological diseases that are difficult to treat.”

“We are excited to evaluate the therapeutic potential of antibodies generated from Biocytogen’s renowned fully human antibody platforms,” said Jude Onyia, Ph.D., Chief Scientific Officer at Neurocrine Biosciences. “We believe this collaboration will help expand our pipeline with antibody-based drugs and ultimately provide patients with improved treatment options.”

### **About Biocytogen**

Biocytogen (Stock Code: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/RenLite®/RenNano®/RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of more than 400,000 fully human antibody sequences against approximately 1,000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).

For more information, please visit the Company’s website at <http://en.biocytogen.com.cn>.

## **Forward-Looking Statements**

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of the directors or the Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.